A ONCE-WEEKLY GLP-1 RA

A ONCE-WEEKLY GLP-1 RA

References

  1. IQVIA. Geographic Prescription Monitor (NOV2019–OCT2020). 2020.
  2. Ozempic® (semaglutide injection) Product Monograph. Novo Nordisk Canada Inc., 2020.
  3. National Institute of Diabetes and Digestive and Kidney Diseases. Eating, Diet, and Nutrition for Gastroparesis. 2018. Available at: https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis/eating-diet-nutrition. Retrieved May, 2020.
  4. Arendt-Nielsen L, et al. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1-2):37-43.
  5. Ley B. Diameter of a human hair. 1999. Available at: http://hypertextbook.com/facts/1999/BrianLey.shtml. Retrieved January, 2018.
  6. Alberta Blue Cross. Interactive Drug Benefit List. 2020. Available at: https://idbl.ab.bluecross.ca/idbl/. Retrieved September, 2020.
  7. BC PharmaCare. Limited Coverage Drugs – semaglutide. 2020. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-semaglutide. Retrieved December 17, 2020.
  8. Manitoba Pharmacare. Manitoba Drug Benefits and Interchangeability Formulary. 2021. Available at: https://www.gov.mb.ca/health/mdbif/. Retrieved January 4, 2021.
  9. Government of New Brunswick. NB Drug Plans Formulary Update. 2020. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf. Retrieved September, 2020.
  10. Indigenous Services Canada. Non-Insured Health Benefits Drug Benefit List. 2020. Available at: https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf. Retrieved September 2020.
  11. Government of Newfoundland and Labrador. Newfoundland and Labrador Prescription Drug Program Drug Product Database. 2019. Available at: https://www.health.gov.nl.ca/health/prescription/newformulary.asp. Retrieved September, 2020.
  12. Government of Nova Scotia. Pharmacare News Bulletins - October Bulletin Vol. 20 - 12. 2020. Available at: https://novascotia.ca/dhw/pharmacare/pharmacare-news-bulletins.asp. Retrieved October, 2020.
  13. Government of Northwest Territories. Health Benefits for Specified Disease Conditions Program. 2020. Available at: https://www.hss.gov.nt.ca/en/services/supplementary-health-benefits/extended-health-benefits-specified-disease-conditions. Retrieved September 2020.
  14. Government of Nunavut. EHB Full Coverage Plan. 2020. Available at: https://gov.nu.ca/health/information/ehb-full-coverage-plan. Retrieved September, 2020.
  15. Government of Ontario. Ontario Drug Benefit Formulary/Comparative Drug Index. 2020. Available at: https://www.formulary.health.gov.on.ca/formulary/. Retrieved September, 2020.
  16. Health PEI. PEI Pharmacare Formulary. 2020. Available at: https://www.princeedwardisland.ca/en/information/health-pei/pei-pharmacare-formulary. Retrieved September, 2020.
  17. RAMQ (official mark of the Régie de l'assurance maladie du Québec). List of Medications. 2020. Available at: https://www.ramq.gouv.qc.ca/en/about-us/list-medications. Retrieved September, 2020.
  18. Saskatchewan Go. Saskatchewan drug plan. 2020. Available at: http://formulary.drugplan.ehealthsask.ca/SearchFormulary. Retrieved October, 2020.
  19. Veterans Affairs Canada. Drug Formulary. 2020. Available at: https://www.veterans.gc.ca/eng/financial-support/medical-costs/treatment-benefits/poc10/search. Retrieved September 2020.
  20. Government of Yukon. Yukon Drug Formulary. 2020. Available at: http://apps.gov.yk.ca/drugs/. Retrieved September, 2020.
  21. Lipscombe L, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Can J Diabetes. 2020;44(7):575-591.
  22. Ahren B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes Endocrinol. 2017;5(5):341-354.
  23. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019;7(11):834-844.
  24. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
  25. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325.

Contact us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225